Last reviewed · How we verify

NCT05820802

High Dimensional Analysis of Immune Cells in Pediatric Patients

Recruiting now Last updated 29 November 2024
What this trial tests

trial in Drug Allergy in 294 participants. Currently enrolling.

Timeline
27 April 2023
Primary endpoint
1 April 2026
1 December 2026

Quick facts

Lead sponsorSeoul National University Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment294
Start date27 April 2023
Primary completion1 April 2026
Estimated completion1 December 2026
Sites1 location across South Korea

Conditions studied

Sponsor

Seoul National University Hospital

Who can join

Adults 2 to 18, any sex, with Drug Allergy or Neuromuscular Blockade. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize immune cells using single-cell transcriptomic analysis in pediatric patients aged 2 to 18 years undergoing general anesthesia who are expected to receive Rocuronium, a non-depolarizing neuromuscular blocking agent, in the event of an allergic reaction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Drug Allergy

Currently open trials in the same condition.

Other Seoul National University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing